Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ophthotech, a privately held biopharmaceutical company, has started the treatment of its first patient with Volociximab, a monoclonal antibody targeting alpha5beta1 integrin, in a Phase I trial for the treatment of wet age-related macular degeneration.
Subscribe to our email newsletter
This trial involves the company’s third compound in clinical development to date. This Phase I trial will assess the safety, tolerability and pharmacokinetic profile of Volociximab.
Recently, Ophthotech enrolled its first patient in a Phase I complement inhibition trial for age-related macular degeneration (AMD) with its anti-C5 complement factor aptamer, ARC1905, in combination with an anti-VEGF agent. A dry AMD trial with ARC1905 is scheduled to commence in 2009.
Samir Patel, president and CEO of Ophthotech, said: “Initiating clinical development of Volociximab, our third compound, is an important milestone, as it demonstrates our commitment to developing and commercializing therapies for both wet and dry AMD in an accelerated manner.”